Related Experiment Video
Updated: Dec 18, 2025
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
Flexural Exanthema From Enfortumab Vedotin
Dinesh Keerty1, Laura Graham2, Elizabeth Haynes2
1Internal and Hospital Medicine, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA.
Abstract:
Urothelial malignancies are commonly treated with platinum-based therapies. Newer trials have tested antimitotic therapies such as enfortumab vedotin as viable treatment therapy for refractory malignany. Enfortumab vedotin targets nectin-4, a member of a family of calcium-dependent, immunoglobulin-like adhesion molecules found in adherens junctions and expressed in various epithelial malignancies, including bladder, breast, lung, ovarian, head/neck, and esophageal cancers. We present a case of a patient with symmetrical drug-related intertriginous and flexural exanthema secondary to enfortumab. He was successfully treated with topical corticosteroids. Cutaneous toxicity appears to be a common adverse reaction in this growing class of antibody-drug conjugates.
Insights
Enfortumab vedotin, an antimitotic therapy, can cause skin reactions like symmetrical drug-related intertriginous and flexural exanthema. Topical corticosteroids effectively treated this adverse event in a patient with urothelial malignancy.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Urothelial malignancies are often treated with platinum-based chemotherapy.
- Novel antimitotic therapies, including enfortumab vedotin, are emerging for refractory cases.
- Enfortumab vedotin targets nectin-4, expressed in various epithelial cancers.
Observation:
- A patient receiving enfortumab vedotin developed symmetrical drug-related intertriginous and flexural exanthema.
- This specific cutaneous toxicity is a notable adverse reaction.
- The patient's condition was successfully managed with topical corticosteroids.
Findings:
- Enfortumab vedotin, an antibody-drug conjugate, is associated with significant cutaneous toxicity.
- Symmetrical drug-related intertriginous and flexural exanthema is a documented side effect.
- Topical corticosteroids provide an effective treatment for this adverse reaction.
Implications:
- Awareness of potential skin toxicities is crucial for clinicians managing patients on enfortumab vedotin.
- Prompt recognition and treatment of cutaneous adverse events can improve patient outcomes.
- Further research into managing side effects of antibody-drug conjugates is warranted.
More Related Videos
Related Concept Videos
01:25Endocarditis II: Clinical Features of Infective Endocarditis
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:27Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
01:29Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
02:45Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
01:15Transcytosis of IgG
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...